HKPD Cellyan Biotechnology Co., Ltd

1.345USD+1.13%Mkt Cap: 3.32M USDP/E: —

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procureme…

Key Statistics

Company
Market Cap3.32M USD
Enterprise Value2.60M USD
Revenue (TTM)13.43M USD
Gross Profit1.39M USD
Net Income (TTM)-1.14M USD
Revenue/Share16.43 USD
Last Price1.345 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees11
CountryUS
SectorHealthcare
IndustryMedical Distribution
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.83
EV/Revenue0.19
P/S0.25
P/B0.16
EPS (TTM)-1.38 USD
EPS (Forward)—
52W Range
1.2001% of range29.00
52W High29.00 USD
52W Low1.200 USD
Profitability
Gross Margin10.32%
Oper. Margin-7.48%
EBITDA Margin-6.84%
Profit Margin-8.46%
ROE-11.85%
ROA-8.84%
ROIC-9.45%
ROCE-10.40%
Growth
Revenue Growth-31.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-751.60K USD
CapEx (TTM)42.54K USD
FCF Margin-48.44%
FCF Yield-196.19%
Net Debt1.04M USD
Net Debt/EBITDA-1.13
Net Debt/FCF—
Balance Sheet
Debt/Equity0.13
Current Ratio3.86
Quick Ratio1.69
Book Value/Sh8.16 USD
Cash/Share0.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 26, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.11M
Float816.58K
Insiders17.34%
Institutions1.26%
Short Interest
Short Ratio0.3d
Short % Float1.02%
Short % Out.0.68%
Shares Short16.87K
Short (prev mo.)3.36K
Technical
SMA 502.108 (-36.2%)
SMA 2008.541 (-84.3%)
Beta—
S&P 52W Chg12.08%
Avg Vol (30d)36.43K
Avg Vol (10d)16.69K
Technical Indicators
RSI (14)31.9
MACD-0.2601
MACD Signal-0.2699
MACD Hist.+0.0098
BB Upper2.339 USD
BB Middle1.740 USD
BB Lower1.141 USD
BB Width68.84%
ATR (14)0.2437 USD
Vol Ratio (20d)0.29x

About Cellyan Biotechnology (NASDAQ: HKPD)

›

Cellyan Biotechnology (NASDAQ: HKPD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 11 employees.

The shares were at 1.345 USD on 19 November 2026, down 94.4% over 52 weeks. Its 52-week range is 1.200 USD to 29.00 USD: the price is 95.4% below the high and 12.1% above the low.

Its market capitalisation is 3.32M USD.

Cellyan Biotechnology reports return on equity of -11.9%, an operating margin of -7.5% and revenue down 31.7% year over year.

Its debt exceeds its cash by 1.04M USD, a debt-to-equity ratio of 0.13. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.